HC Wainwright Expects Higher Earnings for LENZ Therapeutics

Key Points

• HC Wainwright raised its FY2025 earnings per share estimate for LENZ Therapeutics from ($2.84) to ($2.83), maintaining a "Buy" rating with a price target of $48.00.
• LENZ Therapeutics has recently seen interest from institutional investors, with a notable increase in ownership, now totaling 54.32% of the company's stock.
• The company's product candidates, LNZ100 and LNZ101, are currently undergoing Phase III clinical trials aimed at treating presbyopia.

LENZ Therapeutics, Inc. (NASDAQ:LENZ - Free Report) - Investment analysts at HC Wainwright increased their FY2025 earnings per share (EPS) estimates for LENZ Therapeutics in a note issued to investors on Monday, July 28th. HC Wainwright analyst M. Caufield now expects that the company will post earnings per share of ($2.83) for the year, up from their prior estimate of ($2.84). HC Wainwright currently has a "Buy" rating and a $48.00 target price on the stock. The consensus estimate for LENZ Therapeutics' current full-year earnings is ($2.18) per share. HC Wainwright also issued estimates for LENZ Therapeutics' Q4 2025 earnings at ($0.83) EPS, FY2026 earnings at ($2.22) EPS, FY2027 earnings at ($0.15) EPS, FY2028 earnings at $1.06 EPS and FY2029 earnings at $2.18 EPS.

Other equities analysts have also issued reports about the company. Citigroup lifted their price objective on LENZ Therapeutics from $45.00 to $49.00 and gave the stock a "buy" rating in a research note on Thursday. Raymond James Financial boosted their price target on LENZ Therapeutics from $39.00 to $40.00 and gave the company an "outperform" rating in a research note on Thursday. Finally, Piper Sandler began coverage on LENZ Therapeutics in a research note on Monday, April 14th. They issued an "overweight" rating and a $51.00 price target on the stock. Five analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $49.60.

LENZ Therapeutics Stock Up 0.6%

Shares of LENZ stock traded up $0.19 during mid-day trading on Wednesday, reaching $29.96. 1,569,366 shares of the stock traded hands, compared to its average volume of 278,602. The stock's fifty day simple moving average is $31.03 and its two-hundred day simple moving average is $26.98. The company has a market cap of $854.46 million, a price-to-earnings ratio of -15.77 and a beta of 0.42. LENZ Therapeutics has a 1-year low of $16.53 and a 1-year high of $38.93.

LENZ Therapeutics (NASDAQ:LENZ - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The company reported ($0.53) EPS for the quarter, beating analysts' consensus estimates of ($0.58) by $0.05. The firm had revenue of $5.00 million for the quarter, compared to analyst estimates of $5.00 million.

Institutional Investors Weigh In On LENZ Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. KLP Kapitalforvaltning AS bought a new stake in LENZ Therapeutics during the fourth quarter worth $46,000. Tower Research Capital LLC TRC grew its holdings in LENZ Therapeutics by 162.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,860 shares of the company's stock worth $54,000 after buying an additional 1,151 shares in the last quarter. Virtus ETF Advisers LLC bought a new stake in LENZ Therapeutics during the fourth quarter worth $67,000. Banque Transatlantique SA bought a new stake in LENZ Therapeutics during the first quarter worth $119,000. Finally, GAMMA Investing LLC grew its holdings in LENZ Therapeutics by 5,254.1% during the first quarter. GAMMA Investing LLC now owns 5,836 shares of the company's stock worth $150,000 after buying an additional 5,727 shares in the last quarter. Institutional investors own 54.32% of the company's stock.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.